327 related articles for article (PubMed ID: 21461027)
21. Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
Goel SK; Granger D; Bellovich K; Marin M; Qu H; El-Ghoroury M
Transplant Proc; 2011 Sep; 43(7):2784-8. PubMed ID: 21911163
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
[TBL] [Abstract][Full Text] [Related]
23. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Braiteh F; Hymes SR; Giralt SA; Jones R
J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
[No Abstract] [Full Text] [Related]
24. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of transplant-eligible symptomatic multiple myeloma].
Nakaseko C
Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
[No Abstract] [Full Text] [Related]
26. Tandem transplants in the treatment of multiple myeloma. Pro.
Fassas AB; Tricot G
Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
[No Abstract] [Full Text] [Related]
27. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
28. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Sinisalo M; Silvennoinen R; Wirta O
Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
[TBL] [Abstract][Full Text] [Related]
29. Myeloma kidney: improving clinical outcomes?
Haynes R; Leung N; Kyle R; Winearls CG
Adv Chronic Kidney Dis; 2012 Sep; 19(5):342-51. PubMed ID: 22920645
[TBL] [Abstract][Full Text] [Related]
30. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
31. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
[No Abstract] [Full Text] [Related]
32. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
33. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Pendón-Ruiz de Mier MV; Alvarez-Lara MA; Ojeda-López R; Martín-Malo A; Carracedo J; Caballero-Villarraso J; Alonso C; Aljama P
Nefrologia; 2013 Nov; 33(6):788-96. PubMed ID: 24241366
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
35. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
[No Abstract] [Full Text] [Related]
36. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Peinert S; Joyce T; Harrison SJ
Bone Marrow Transplant; 2011 May; 46(5):764-5. PubMed ID: 20676149
[No Abstract] [Full Text] [Related]
37. Current therapeutic strategy for multiple myeloma.
Suzuki K
Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
[TBL] [Abstract][Full Text] [Related]
38. [Renal disease in multiple myeloma].
Hiromura K; Nojima Y
Nihon Rinsho; 2007 Dec; 65(12):2229-34. PubMed ID: 18069265
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
40. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
Björkstrand B; Gahrton G
Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
